Clinical trials: Respiratory Disorder
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
Nasal Polyps
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- ANCHOR-1 (NCT05274750)
- Testing
- Depemokimab (GSK3511294)
- Where
- 105 sites in United States, Argentina and 9 more
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
Electro Flo 5000 and Vest Therapy
It is the goal of the proposed study to compare the efficacy, as assessed primarily by sputum weight, of these two different devices (the Electroflo 500 and VEST therapy) for airway clearance (AC) in CF patients with mild to…
- Trial name
- EF/Vest (NCT02277626)
- Testing
- Electro Flo 5000, Incourage Vest System
- Volunteers
- 15 people
- Sponsor
- Stanford University
Influenza
A Study of Influenza Virus Vaccines in Children and Adults
The purpose of this study is to describe the immunogenicity of the prototype Quadrivalent Influenza Vaccine (QIV) compared with the 2009-2010 Trivalent Influenza Vaccine (TIV) and the 2008-2009 TIV among children and adults.
- Trial name
- NCT00988143
- Testing
- 2009-2010 Trivalent Influenza Virus Vaccine, 2008-2009 Trivalent Influenza Virus Vaccine, Quadrivalent Influenza Virus Vaccine
- Where
- 4 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Asthma
Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation
Comparing one versus two doses of oral dexamethasone for the treatment of asthma in the pediatric emergency department.
- Trial name
- R2D2 (NCT02725008)
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Geoffrey W Jara-Almonte
Cystic Fibrosis
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
The purpose of this actual use human factors (HF) study is to validate the approved US TOBI Podhaler Instructions for Use (IFU), by establishing that the IFU effectively communicates the information necessary to achieve safe and…
- Trial name
- NCT02178540
- Testing
- Tobi Podhaler
- Where
- 13 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Infant, Newborn, Infant, Small for Gestational Age
Hydrocortisone for BPD
The Hydrocortisone and Extubation study will test the safety and efficacy of a 10 day course of hydrocortisone for infants who are less than 30 weeks estimated gestational age and who are intubated at 14-28 days of life.
- Conditions
- Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature
- Trial name
- NCT01353313
- Testing
- Hydrocortisone
- Where
- 20 sites in United States
- Volunteers
- 800 people
- Sponsor
- NICHD Neonatal Research Network
Pneumonia
Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application
The Curetis Unyvero LRT55 Application is intended to detect and to identify genes of 21 microorganisms and 19 genes associated with antibiotic resistance in 4 hours.
- Trial name
- LRT55 (NCT01922024)
- Testing
- LRT55 Testing
- Where
- 9 sites in United States
- Volunteers
- 2,124 people
- Sponsor
- Curetis GmbH
COVID-19
SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Conversational Agent Study
The long-term objective of SCALE-UP II is to increase the reach, uptake, and sustainability of COVID-19 testing among underserved populations.
- Trial name
- NCT05533359
- Testing
- Text-Messaging (TM), Conversational Agent (CA), Patient Navigation (PN)
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- University of Utah
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
- Trial name
- NCT02888080
- Testing
- ACZ885
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small-Cell Lung Carcinoma
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic nonsquamous non-small cell…
- Trial name
- NCT02578680
- Testing
- Pembrolizumab 200 mg, Cisplatin, Carboplatin
- Volunteers
- 616 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
The main aim of this study is to evaluate the safety and tolerability of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR) mutation(s)…
- Trial name
- NCT02044380
- Testing
- Afatinib
- Where
- 5 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Acute Lung Injury, Acute Respiratory Distress Syndrome
The Role of Circulating Soluble CD74 in Acute Lung Injury
Efforts to identify circulating factors that predict severity of acute lung injury/acute respiratory distress syndrome（ALI/ARDS） patients is unrevealing.
- Trial name
- NCT02201446
- Where
- China
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Asthma
A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)
A study to compare the bronchodilatory effect of a single dose of Mometasone Furoate/Formoterol Fumarate (MF/F) pressurized metered dose inhaler (MDI) delivered with and without an AeroChamber Plus® with Flow-Vu® Anti-Static…
- Trial name
- NCT01258803
- Testing
- Formoterol Fumarate DPI, Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer, Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
- Volunteers
- 92 people
- Sponsor
- Organon and Co
Infant, Newborn, Hypoxia, Brain
Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)
The Optimizing Cooling trial will compare four whole-body cooling treatments for infants born at 36 weeks gestational age or later with hypoxic-ischemic encephalopathy: (1) cooling for 72 hours to 33.5°C; (2) cooling for 120…
- Conditions
- Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic
- Trial name
- NCT01192776
- Testing
- Whole-body Cooling
- Where
- 19 sites in United States
- Volunteers
- 364 people
- Sponsor
- NICHD Neonatal Research Network
Bronchiolitis, Bronchiolitis, Viral
Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
This study will compare the novel methods of NS and BS with the standard technique of nasophayngeal aspiration (NPA) and routine ETT suction.
- Conditions
- Bronchiolitis, Bronchiolitis, Viral, RSV Infection, Respiratory Failure
- Trial name
- RSV-SAM (NCT03062917)
- Testing
- Nasal and Bronchial Sampling
- Where
- United Kingdom
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
COVID-19
Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers
The aim of this multi-part Phase 1 study is to evaluate the drug-drug interaction (DDI) potential of ALG-097558 via co-administration with a P-gp substrate (dabigatran) and a CYP3A4 inhibitor/P-gp inhibitor (itraconazole).
- Trial name
- NCT06945276
- Testing
- ALG-097558, Dabigatran, Itraconazole
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Persistent Fetal Circulation Syndrome
Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn
The purpose of this pilot study is to determine a safe dose of milrinone to use in a larger study of babies with persistent pulmonary hypertension of the newborn (PPHN).
- Trial name
- NCT01088997
- Testing
- Milrinone Lactate
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital of Philadelphia
Pertussis, Tetanus
Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose
The purpose of this study is to collect additional immunogenicity and safety data on re-dosing with Tdap vaccine (ADACEL®) in a continuing effort to address the public health need to establish broader population immunity against…
- Conditions
- Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00712959
- Testing
- Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)
- Where
- 7 sites in Canada
- Volunteers
- 769 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Carcinoma, Non-Small-Cell Lung
Genetic Predictors of Benefit to Pembrolizumab
The primary objective is to determine if mutation load underlies sensitivity to pembrolizumab alone and in combination with chemotherapy.
- Trial name
- NCT02710396
- Testing
- Pembrolizumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Columbia University
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.